Novartis reported Thursday that a Phase III trial of iptacopan met its primary endpoint in paroxysmal nocturnal hemoglobinuria (PNH) – the company’s second win in this indication in as many months.
https://www.pharmalive.com/wp-content/uploads/2021/09/Novartis-Adds-to-Optogenetics-Portfolio-with-Arctos-Medical-Buy-BioSpace-9-21-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-12-08 11:30:082022-12-08 12:11:44Novartis secures second Phase III PNH win in as many months
